Zecuity

Zecuity is a sumatriptan-based iontophoretic transdermal system developed by NuPathe and later acquired by Teva for the acute treatment of migraine with or without aura in adults. It consists of a single-use, battery-powered patch that utilizes a low-level electrical current (iontophoresis) to deliver 6.5 mg of sumatriptan succinate through the skin over a 4-hour period. This delivery method bypasses the gastrointestinal tract, making it a suitable option for patients who experience migraine-related nausea or vomiting. Although approved by the FDA in January 2013, Teva voluntarily suspended sales and distribution of the product in 2016 following reports of serious application-site reactions, including skin burns and scarring.

Brand names

Zecuity

Other names

sumatriptan iontophoretic transdermal systemsumatriptan succinate iontophoretic transdermal patch